Figure 3: Health economics and market access in the development process. ... Value-driven drug development—unlocking the value of your pipeline. McKinsey and Company. 2011. 2.

To ensure market access is integrated with other functions and across geographies, and is an early part of future drug development, companies must understand what is required, internally and ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & ...

Despite substantial investments in groundbreaking treatments, companies struggle to communicate value early and to the right ...

President Trump just issued an executive order to rebalance the global pharmaceutical market — by tying U.S. drug prices to ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Oxana Iliach is a Senior Director of Regulatory Strategy at Certara (PA, USA), a biotech company that offers comprehensive solutions for transforming and accelerating drug development. In her spare ...

Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug ...

Explore Morningstar’s 2025 Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and growth forecasts through 2029.

JUNE 10, 2025 — UTSA researchers in the Max and Minnie Tomerlin Voelcker CIDD Preclinical Pharmacology Core for Accelerated ...